Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Objective. A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Venkat, Klein, Christian, Isenberg, David A., Glennie, Martin J., Cambridge, Geraldine, Cragg, Mark S., Leandro, Maria J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Basic and Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808665/
https://www.ncbi.nlm.nih.gov/pubmed/28407142
http://dx.doi.org/10.1093/rheumatology/kex067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808665/
https://www.ncbi.nlm.nih.gov/pubmed/28407142
http://dx.doi.org/10.1093/rheumatology/kex067

Ejemplares similares